Brief: Hansa Biopharma Appoints Evan Ballantyne As CFO
22/02/2024 14:23
Feb 22 (Reuters) - Hansa Biopharma AB HNSA.ST :
* EVAN BALLANTYNE TO JOIN HANSA BIOPHARMA AS CHIEF FINANCIAL
OFFICER
* BALLANTYNE SUCCEEDS DONATO SPOTA, WHO, AS PREVIOUSLY
ANNOUNCED,
WILL LEAVE COMPANY ON 28 FEBRUARY
Source text for Eikon: ID:nWkr9M7Dvv
Further company coverage: HNSA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS